Trojani et al. (2019) described that ABCD3 is significantly under-expressed in the chronic phase of chronic myeloid leukemia in patients after 12 months of treatment with nilotinib [46]. This evidence concerns the gene ABCD3 and chronic myelogenous leukemia, BCR-ABL1 positive.